<DOC>
	<DOCNO>NCT00160654</DOCNO>
	<brief_summary>Community base study assess safety efficacy levetiracetam partial onset seizure . The optimal dose daily clinical practice use .</brief_summary>
	<brief_title>Open Label Safety Efficacy Study Levetiracetam Patients With Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Subjects epilepsy experience partial seizure , whether secondarily generalize . Subjects must present 3 42 partial seizure three month prior protocol Visit 1 . Use one ( 1 ) , two ( 2 ) concomitant market AEDs time trial entry . Subjects vigabatrin , whose visual field assess per recommendation manufacturer , i.e . every 6 month . Presence known pseudoseizures within last year . Presence progressive cerebral disease , progressively degenerative neurological disease , cerebral tumor . Uncountable seizure ( cluster ) history convulsive status epilepticus within last five year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Partial Onset Seizures</keyword>
	<keyword>Keppra</keyword>
	<keyword>Levetiracetam</keyword>
</DOC>